Monitor for initiation of the ovarian cancer arm in the Phase 1/2a expansion phase and any future clinical data readouts. The preclinical synergy data is supportive but early; clinical validation is the next catalyst.
Price Chart
Executive Summary
BioLineRx and Hemispherian presented preclinical data at ESMO 2026 showing GLIX1 synergizes with multiple PARP inhibitors in HR-proficient ovarian cancer cell lines and a PDX model. The data supports a potential expansion of GLIX1's addressable market beyond glioblastoma into ovarian cancer, but remains preclinical with no new clinical data or financial figures disclosed.
Key Facts
- GLIX1 combined with three PARP inhibitors (olaparib, veliparib, niraparib) showed reproducible synergy across HR-proficient ovarian cancer cell lines with ZIP synergy scores ranging from 10.9 to 43.2.
- In an HR-proficient ovarian cancer PDX model, low-dose GLIX1 (50 mg/kg) plus olaparib (10 mg/kg) demonstrated statistically significant tumor growth inhibition vs vehicle control and comparable to cisplatin.
- GLIX1 demonstrated tumor-to-plasma concentration ratios of approximately 50% in ovarian tumor tissue following oral administration.
- BioLineRx plans to add an ovarian cancer arm in the expansion phase of its ongoing Phase 1/2a clinical trial (NCT07464925).
- GLIX1 is currently being evaluated in a Phase 1/2a clinical trial in glioblastoma, with three dose-level patient cohorts already enrolled.
Financial Impact
No financial figures disclosed; preclinical data only. Potential market expansion if clinical data supports ovarian cancer indication.
Risk Factors
- Preclinical data may not translate to clinical efficacy in humans.
- GLIX1 is still in early-stage clinical development (Phase 1/2a) with no approved products generating revenue from this asset.
- Competition from existing PARP inhibitors and other DNA damage response agents in ovarian cancer.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001178913-26-004823 |
| Document: zk2636256.htm | 0001178913-26-004823 |
| Document: 0001178913-26-004823-index-headers.html | 0001178913-26-004823 |
| Document: 0001178913-26-004823-index.html | 0001178913-26-004823 |
| Document: 0001178913-26-004823.txt | 0001178913-26-004823 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | 6-K | $2.04 | awaiting T+20 | — | $2.03 (−0.49%) |
Oct 5, 2026 22d ago | EFFECT | $2.32 | awaiting T+20 | — | $2.03 (+12.50%) |
Sep 25, 2026 4w ago | F-1 | $2.43 $2.00 | ▼ −17.70% | ▼ −17.66% | $2.03 (−16.46%) |
Sep 10, 2026 6w ago | 6-K | $2.57 $2.21 | ▼ −13.99% | ▼ −16.12% | $2.03 (−21.00%) |
Aug 31, 2026 8w ago | 424B5 | $2.80 $2.36 | ▲ +15.71% | ▲ +15.34% | $2.03 (+27.50%) |
Aug 31, 2026 8w ago | 6-K | $2.80 $2.36 | ▲ +15.71% | ▲ +15.34% | $2.03 (+27.50%) |
Aug 31, 2026 8w ago | 6-K | $2.80 $2.36 | ▲ +15.71% | ▲ +15.34% | $2.03 (+27.50%) |
Aug 28, 2026 8w ago | 6-K | $2.60 $2.43 | ▲ +6.54% | ▲ +6.80% | $2.03 (+21.92%) |
Aug 28, 2026 8w ago | Press Release | $2.60 $2.43 | ▲ +6.54% | ▲ +6.80% | $2.03 (+21.92%) |
Jul 8, 2026 15w ago | 6-K | $3.01 $2.72 | ▼ −9.73% | ▼ −13.01% | $2.03 (−32.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers